Clinical trials: Digestive System
Crohn's Disease, Ulcerative Colitis
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
The purpose of this study is to evaluate the long-term safety and clinical status of pediatric patients with Inflammatory Bowel Disease (IBD).
- Conditions
- Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
- Trial name
- DEVELOP (NCT00606346)
- Testing
- Anti TNF therapy including infliximab, No Biologics
- Where
- 62 sites in United States, Canada
- Volunteers
- 4,970 people
- Sponsor
- Janssen Biotech, Inc.
Colitis, Ulcerative, Crohn's Disease
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative colitis (UC) and Crohn's disease (CD).
- Trial name
- NCT02620046
- Testing
- Vedolizumab SC
- Where
- 301 sites in United States, Argentina and 31 more
- Volunteers
- 746 people
- Sponsor
- Takeda
Primary Biliary Cirrhosis
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid.
- Trial name
- NCT01389973
- Testing
- ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg
- Where
- 10 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
The proposed study is designed to evaluate Pillcam regimen in Crohn's disease patients, using the PillCam Colon system.
- Trial name
- RD-207 (NCT01576120)
- Testing
- bowel prep regimen first boost 6 oz. and second boost 3 oz., bowel prep regimen first boost 3 oz. and second boost 6 oz.
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Medtronic - MITG
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR)…
- Trial name
- ENVISION (NCT00909727)
- Testing
- Ivacaftor
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 52 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Liver Fibrosis, Liver Steatosis
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
Evaluate the feasibility of the Liver Incyte system for liver elasticity measurement in healthy volunteers and patients with liver fibrosis.
- Trial name
- NCT03957070
- Testing
- Liver Incyte
- Where
- 2 sites in United States, Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sonic Incytes
Ulcerative Colitis
TP0501 - Pharmaco-Scintigraphic-Study
This is a Phase I, open-label, single-site trial to evaluate the drug release, using Scintigraphic images and mesalazine plasma levels (PK) in healthy subjects.
- Trial name
- NCT02306772
- Testing
- TP05 Coating A, TP05 Coating B
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tillotts Pharma AG
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Colitis, Ulcerative
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).
- Trial name
- NCT00487539
- Testing
- Golimumab 100 mg, Golimumab 200 mg, Golimumab 400 mg
- Where
- 200 sites in United States, Australia and 23 more
- Volunteers
- 1,065 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention.
- Trial name
- AMAY (NCT05509777)
- Testing
- Mirikizumab
- Where
- 81 sites in United States, Austria and 14 more
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo…
- Trial name
- NCT03420781
- Testing
- Relamorelin
- Where
- 337 sites in United States, Argentina and 24 more
- Volunteers
- 467 people
- Sponsor
- Allergan
Hepatitis C, Chronic
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment
This randomized, double blind, phase II study will evaluate the efficacy and safety of two doses of RO5024048 in combination with ritonavir-boosted danoprevir and Pegasys (peginterferon alpha-2a) and Copegus (ribavirin) in…
- Trial name
- NCT01579019
- Testing
- RO5024048, danoprevir, peginterferon alfa-2a [Pegasys]
- Sponsor
- Hoffmann-La Roche
IBD (Inflammatory Bowel Disease)
Human and Microbial Determinants of the Onset of IBD Flares
This study will collect longitudinal biological samples and survey data to identify the triggers of IBD flares.
- Trial name
- NCT06967311
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Viome
Hepatitis B, Chronic
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).
- Trial name
- ASPIRE-202 (NCT07654283)
- Testing
- AHB-137
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 70 people
- Sponsor
- AusperBio Therapeutics Inc.
Fecal Incontinence
A Feasibility Study of a Fecal Incontinence Management System for Medical Use
The purpose of this feasibility study is to evaluate the performance and skin-friendliness of the barrier of the Fecal Incontinence Management System.
- Trial name
- NCT00556972
- Testing
- Fecal Incontinence Management System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Coloplast A/S
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Hepatic Insufficiency
A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)
The purpose of this study is to learn what happens to bomedemstat (MK-3543) in a person's body over time. Researchers will compare what happens to bomedemstat in the body when it is given to participants with mild or moderate…
- Trial name
- NCT07049939
- Testing
- Bomedemstat
- Where
- 3 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Cystic Fibrosis
Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
Cystic Fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The encoded protein, CFTR, is an epithelial chloride ion channel responsible for aiding in the regulation of salt…
- Trial name
- NCT01161537
- Testing
- VX-770
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Ulcerative Colitis
Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects
This study evaluates the safety and tolerability of TOP1288 oral single ascending and multiple doses in healthy subjects.
- Trial name
- NCT03071081
- Testing
- TOP1288
- Where
- United Kingdom
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Topivert Pharma Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.